Gainers
- PHAXIAM Therapeutics S.A. (NASDAQ:PHXM) shares surged 46.7% to $0.64 in pre-market trading after gaining 6% on Wednesday.
- Capri Holdings Limited (NYSE:CPRI) rose 26.8% to $43.88 in pre-market trading. Tapestry (NYSE:TPR) is nearing a deal to buy Capri Holdings, the Wall Street Journal reported.
- EBET, Inc. (NASDAQ:EBET) shares gained 23.5% to $0.0489 in pre-market trading after jumping over 37% on Wednesday.
- AppLovin Corporation (NASDAQ:APP) shares rose 22.6% to $36.06 in pre-market trading after the company reported better-than-expected second-quarter results.
- Vistagen Therapeutics, Inc. (NASDAQ:VTGN) rose 19.1% to $8.38 in pre-market trading. AffaMed said that its partner Vistagen Therapeutics reported positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol nasal spray in adults diagnosed with social anxiety disorder.
- MDxHealth SA (NASDAQ:MDXH) shares gained 18.1% to $4.12 in pre-market trading after the company said Cigna has expanded commercial and Medicare Advantage coverage to include the Company’s Select mdx for Prostate Cancer test.
- Avalo Therapeutics, Inc. (NASDAQ:AVTX) gained 15.7% to $0.1765 in pre-market trading after falling over 8% on Wednesday.
- T2 Biosystems, Inc. (NASDAQ:TTOO) gained 15.3% to $0.3950 in pre-market trading after gaining over 10% on Wednesday. T2 Biosystems regained compliance with Nasdaq's market value of listed securities requirement.
- AERWINS Technologies Inc. (NASDAQ:AWIN) shares climbed 14.5% to $0.2599 in pre-market trading after gaining around 6% on Wednesday.
- WeWork Inc. (NYSE:WE) shares rose 10.2% to $0.1421 in pre-market trading. WeWork shares fell over 38% on Wednesday after the company reported worse-than-expected second-quarter financial results.
Losers
- Galera Therapeutics, Inc. (NASDAQ:GRTX) fell 81.7% to $0.4094 in pre-market trading after the company received Complete Response Letter from the U.S. FDA for avasopasem manganese.
- Amyris, Inc. (NASDAQ:AMRS) shares fell 56.2% to $0.15 in pre-market trading after the company filed for bankruptcy in the US.
- Origin Materials, Inc. (NASDAQ:ORGN) fell 53.1% to $2.03 in pre-market trading after the company reported mixed second-quarter financial results.
- SciSparc Ltd. (NASDAQ:SPRC) shares fell 39.4% to $0.2998 in pre-market trading after the company reported a proposed underwritten public offering of approximately $1.3 million.
- 180 Life Sciences Corp. (NASDAQ:ATNF) fell 24.9% to $0.6342 in pre-market after gaining around 12% on Wednesday.
- Renovaro Biosciences Inc. (NASDAQ:RENB) fell 24.4% to $1.17 in pre-market trading. Renovaro Biosciences shares jumped 82% on Wednesday after the company and AI-focused GEDi Cube announced a binding, exclusive letter of intent to merge.
- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) fell 24.2% to $ 0.25 in pre-market trading after the company reported second-quarter results.
- Innoviz Technologies Ltd. (NASDAQ:INVZ) shares fell 17.5% to $2.59 in pre-market trading as the company priced $65 million upsized public offering of 26 million ordinary shares at $2.50 per share.
- Greenwave Technology Solutions, Inc. (NASDAQ:GWAV) fell 13.5% to $0.90 in pre-market trading.
- Magnite, Inc. (NASDAQ:MGNI) fell 13.2% to $10.71 in pre-market trading after the company reported second-quarter financial results.
Now Read This: Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday
AVTXAvalo Therapeutics Inc
$18.01-3.17%
AWINAERWINS Technologies Inc
$0.00020-100.0%
CPRICapri Holdings Ltd
$26.110.33%
EBETEBET Inc
$0.00010-100.0%
GRTXGalera Therapeutics Inc
$0.0240-%
GWAVGreenwave Technology Solutions Inc
$6.24-7.08%
INVZInnoviz Technologies Ltd
$1.21-2.82%
MDXHMDxHealth SA
$3.330.15%
MGNIMagnite Inc
$15.95-2.18%
MTNBMatinas BioPharma Holdings Inc
$0.7400-6.33%
ORGNOrigin Materials Inc
$0.3901-5.57%
SPRCSciSparc Ltd
$1.64-10.9%
TPRTapestry Inc
$123.920.58%
TTOOT2 Biosystems Inc
$0.0127-90.5%
VTGNVistagen Therapeutics Inc
$4.302.47%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
